{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:28:37Z","timestamp":1791095317331,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Lowering low-density lipoprotein (LDL)-cholesterol reduces cardiovascular risk. International lipid management guidelines recommend LDL-cholesterol goals or thresholds for initiating lipid-lowering therapy. However, contemporary real-world studies have shown that many high- and very high-risk patients are not attaining LDL-cholesterol goals and are not receiving intensive lipid-lowering therapies. In this review, recent examples of implementation strategies for optimising lipid management are discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Implementation studies are heterogenous in their strategies and design. At the clinician level, multidisciplinary team-based care (including multidisciplinary lipid clinics), pharmacist- or nurse-led interventions, decision-support algorithms or protocols, and educational initiatives have shown potential to improve lipid management. Various strategies to improve patient adherence to lipid-lowering therapies have demonstrated at least short-term efficacy, including education, shared decision-making, behavioural support and nudges. Electronic health records can be leveraged at low cost to identify patients requiring initiation or intensification of lipid-lowering therapies, but the optimal method of integrating automated alerts or nudges to influence decision-making requires further research. Moreover, telehealth and remote care delivery models can improve access to healthcare and facilitate lipid-lowering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Multifaceted strategies with a systematic approach to targeting clinician, patient and system related factors can be successful in improving lipid management. Future implementation research should evaluate longer-term outcomes and follow implementation science theories, models and\/or frameworks at all stages. By doing so, ongoing implementation studies will help researchers better understand the impact, sustainability and scalability of strategies, and where barriers and facilitators to lipid management may exist in other contexts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-024-02174-8","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T07:09:43Z","timestamp":1736320183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Learnings from Implementation Strategies to Improve Lipid Management"],"prefix":"10.1007","volume":"27","author":[{"given":"Nick S. R.","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofei Trophy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"25","key":"2174_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"key":"2174_CR2","doi-asserted-by":"crossref","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38(32):2459\u20132472.","DOI":"10.1093\/eurheartj\/ehx144"},{"issue":"24","key":"2174_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330.","journal-title":"Eur Heart J"},{"issue":"6","key":"2174_CR4","doi-asserted-by":"publisher","first-page":"e008552","DOI":"10.1161\/CIRCOUTCOMES.121.008552","volume":"15","author":"N Wang","year":"2022","unstructured":"Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"13","key":"2174_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","volume":"76","author":"MJ Domanski","year":"2020","unstructured":"Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2174_CR6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jacc.2020.08.004","volume":"76","author":"MD Shapiro","year":"2020","unstructured":"Shapiro MD, Bhatt DL. \u201cCholesterol-Years\u201d for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76(13):1517\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2174_CR7","doi-asserted-by":"publisher","first-page":"e2025675","DOI":"10.1001\/jamanetworkopen.2020.25675","volume":"3","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE. Statins and LDL-C in secondary prevention-so much progress, so far to go. JAMA Netw Open. 2020;3(11):e2025675.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2174_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"24","key":"2174_CR9","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"key":"2174_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"G De Backer","year":"2019","unstructured":"De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135\u201346.","journal-title":"Atherosclerosis"},{"key":"2174_CR11","doi-asserted-by":"crossref","unstructured":"Nelson AJ, Haynes K, Shambhu S, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol 2022;79(18):1802\u20131813.","DOI":"10.1016\/j.jacc.2022.02.048"},{"issue":"11","key":"2174_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"2174_CR13","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"2174_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","volume":"16","author":"AM Navar","year":"2023","unstructured":"Navar AM, Kolkailah AA, Gupta A, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a Retrospective Cohort Study of 322 153 patients. Circ Cardiovasc Qual Outcomes. 2023;16(8):533\u201343.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"2174_CR15","doi-asserted-by":"publisher","first-page":"e010376","DOI":"10.1161\/JAHA.118.010376","volume":"8","author":"LD Colantonio","year":"2019","unstructured":"Colantonio LD, Rosenson RS, Deng L, et al. Adherence to statin therapy among US adults between 2007 and 2014. J Am Heart Assoc. 2019;8(1):e010376.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2174_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","volume":"4","author":"F Rodriguez","year":"2019","unstructured":"Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206\u201313.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2174_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ehjqcco\/qcab024","volume":"8","author":"HT May","year":"2022","unstructured":"May HT, Knowlton KU, Anderson JL, Lapp\u00e9 DL, Bair TL, Muhlestein JB. High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study. Eur Heart J Qual Care Clin Outcomes. 2022;8(3):352\u201360.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"4","key":"2174_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/clc.23988","volume":"46","author":"AL Catapano","year":"2023","unstructured":"Catapano AL, De Caterina R, Jukema JW, et al. Addressing current challenges in optimization of lipid management following an ACS event: outcomes of the ACS EuroPath III initiative. Clin Cardiol. 2023;46(4):407\u201315.","journal-title":"Clin Cardiol"},{"issue":"1","key":"2174_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41569-021-00645-x","volume":"19","author":"MN Sarkies","year":"2022","unstructured":"Sarkies MN, Jones LK, Gidding SS, Watts GF. Improving clinical practice guidelines with implementation science. Nat Rev Cardiol. 2022;19(1):3\u20134.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2174_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","volume":"30","author":"GF Watts","year":"2021","unstructured":"Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ. 2021;30(3):324\u201349.","journal-title":"Heart Lung Circ"},{"issue":"12","key":"2174_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","volume":"20","author":"GF Watts","year":"2023","unstructured":"Watts GF, Gidding SS, Hegele RA, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023;20(12):845\u201369.","journal-title":"Nat Rev Cardiol"},{"key":"2174_CR22","doi-asserted-by":"publisher","unstructured":"Jones LK, Gidding SS, Santos RD, Libby P, Watts GF, Sarkies MN. Application of implementation science for improving the utilization of an international clinical practice guidance on familial hypercholesterolemia.\u00a0J Clin Lipidol. 2024;18(4):e525\u201336. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.010.","DOI":"10.1016\/j.jacl.2024.03.010"},{"issue":"7","key":"2174_CR23","doi-asserted-by":"publisher","first-page":"e008109","DOI":"10.1161\/CIRCOUTCOMES.121.008109","volume":"14","author":"KI Galaviz","year":"2021","unstructured":"Galaviz KI, Barnes GD. Implementation science opportunities in cardiovascular medicine. Circ Cardiovasc Qual Outcomes. 2021;14(7):e008109.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"19","key":"2174_CR24","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1161\/CIR.0000000000001096","volume":"146","author":"N Moise","year":"2022","unstructured":"Moise N, Cen\u00e9 CW, Tabak RG, et al. Leveraging implementation science for cardiovascular health equity: a scientific statement from the american heart association. Circulation. 2022;146(19):e260\u201378.","journal-title":"Circulation"},{"issue":"25","key":"2174_CR25","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1016\/j.jacc.2024.04.034","volume":"83","author":"CN Hess","year":"2024","unstructured":"Hess CN, Daffron A, Nehler MR, et al. Randomized trial of a vascular care team vs education for patients with peripheral artery disease. J Am Coll Cardiol. 2024;83(25):2658\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2174_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43058-021-00135-8","volume":"2","author":"LK Jones","year":"2021","unstructured":"Jones LK, McMinn M, Kann D, et al. Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis. Implement Sci Commun. 2021;2(1):32.","journal-title":"Implement Sci Commun"},{"key":"2174_CR27","doi-asserted-by":"publisher","unstructured":"Khatib R, Khan M, Barrowcliff A, et al. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors. Open Heart. 2022;9(1):e001931. https:\/\/doi.org\/10.1136\/openhrt-2021-001931.","DOI":"10.1136\/openhrt-2021-001931"},{"key":"2174_CR28","doi-asserted-by":"crossref","unstructured":"Tucker MA, Meyer A, Bitonti M, Supple M, Cain B. Pharmacist optimization of lipid therapy in patients with peripheral vascular disease. Am J Health Syst Pharm. 2024;81(Supplement_4):S152-s159.","DOI":"10.1093\/ajhp\/zxae097"},{"key":"2174_CR29","doi-asserted-by":"publisher","unstructured":"Hart M, Rees J, Newton JL, Stansby G, Mackay K, Luvai A. Lipid-lowering optimisation for secondary prevention vascular and diabetic foot patients in a pharmacist-led clinic.\u00a0J Clin Lipidol. 2024;18(4):e572\u20138. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.008.","DOI":"10.1016\/j.jacl.2024.03.008"},{"issue":"2","key":"2174_CR30","doi-asserted-by":"publisher","first-page":"e000607","DOI":"10.1136\/openhrt-2017-000607","volume":"4","author":"M Snaterse","year":"2017","unstructured":"Snaterse M, Jorstad HT, Heiligenberg M, et al. Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration. Open Heart. 2017;4(2):e000607.","journal-title":"Open Heart"},{"issue":"5","key":"2174_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/1474515119831511","volume":"18","author":"S Ruiz-Bustillo","year":"2019","unstructured":"Ruiz-Bustillo S, Ivern C, Badosa N, et al. Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: a pilot randomized controlled trial. Eur J Cardiovasc Nurs. 2019;18(5):366\u201374.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"5","key":"2174_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12471-023-01851-7","volume":"32","author":"A Omar Khader","year":"2024","unstructured":"Omar Khader A, van Trier T, van der Brug S, et al. Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome. Neth Heart J. 2024;32(5):206\u201312.","journal-title":"Neth Heart J"},{"issue":"3","key":"2174_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jjcc.2021.10.005","volume":"79","author":"S Nakao","year":"2022","unstructured":"Nakao S, Ishihara T, Tsujimura T, et al. Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome.\u00a0J Cardiol. 2022;79(3):391\u20139. https:\/\/doi.org\/10.1016\/j.jjcc.2021.10.005.","journal-title":"J Cardiol"},{"issue":"2","key":"2174_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cjco.2019.12.002","volume":"2","author":"A Langer","year":"2020","unstructured":"Langer A, Tan M, Goodman SG, et al. GOAL Canada: physician education and support can improve patient management. CJC Open. 2020;2(2):49\u201354.","journal-title":"CJC Open"},{"key":"2174_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2021.03.013","volume":"323","author":"S Zafeiropoulos","year":"2021","unstructured":"Zafeiropoulos S, Farmakis I, Kartas A, et al. Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: a pragmatic randomized controlled trial. Atherosclerosis. 2021;323:37\u201343.","journal-title":"Atherosclerosis"},{"issue":"10","key":"2174_CR36","first-page":"1053","volume":"25","author":"SM Abughosh","year":"2019","unstructured":"Abughosh SM, Vadhariya A, Johnson ML, et al. Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence. J Manag Care Spec Pharm. 2019;25(10):1053\u201362.","journal-title":"J Manag Care Spec Pharm"},{"key":"2174_CR37","doi-asserted-by":"crossref","unstructured":"Perez de Isla L, Liberopoulos E, Dovizio M, Veronesi C, Degli Esposti L, Zambon A. Differential adherence to free and single-pill combination of rosuvastatin\/ezetimibe: findings from a real-world analysis in Italy. Adv Ther 2024;41(8):3407\u20133418.","DOI":"10.1007\/s12325-024-02916-8"},{"issue":"19","key":"2174_CR38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/CIRCULATIONAHA.121.056161","volume":"145","author":"CK Chow","year":"2022","unstructured":"Chow CK, Klimis H, Thiagalingam A, et al. Text messages to improve medication adherence and secondary prevention after acute Coronary Syndrome: the TEXTMEDS Randomized Clinical Trial. Circulation. 2022;145(19):1443\u201355.","journal-title":"Circulation"},{"key":"2174_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2021.11.001","volume":"244","author":"BD Horne","year":"2022","unstructured":"Horne BD, Muhlestein JB, Lapp\u00e9 DL, et al. Behavioral nudges as patient decision support for medication adherence: the ENCOURAGE randomized controlled trial. Am Heart J. 2022;244:125\u201334.","journal-title":"Am Heart J"},{"issue":"3","key":"2174_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11606-016-3858-0","volume":"32","author":"A Reddy","year":"2017","unstructured":"Reddy A, Huseman TL, Canamucio A, et al. Patient and partner feedback reports to improve statin medication adherence: a randomized control trial. J Gen Intern Med. 2017;32(3):256\u201361.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2174_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamacardio.2022.4373","volume":"8","author":"S Adusumalli","year":"2023","unstructured":"Adusumalli S, Kanter GP, Small DS, et al. Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial. JAMA Cardiol. 2023;8(1):23\u201330.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2174_CR42","first-page":"40","volume":"6","author":"S Adusumalli","year":"2021","unstructured":"Adusumalli S, Westover JE, Jacoby DS, et al. Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial. JAMA Cardiol. 2021;6(1):40\u20138.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"2174_CR43","doi-asserted-by":"publisher","first-page":"e010335","DOI":"10.1161\/CIRCOUTCOMES.123.010335","volume":"17","author":"NN Shah","year":"2024","unstructured":"Shah NN, Ghazi L, Yamamoto Y, et al. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): a randomized clinical trial. Circ Cardiovasc Qual Outcomes. 2024;17(5):e010335.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"18","key":"2174_CR44","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1001\/jama.2015.14850","volume":"314","author":"DA Asch","year":"2015","unstructured":"Asch DA, Troxel AB, Stewart WF, et al. Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial. JAMA. 2015;314(18):1926\u201335.","journal-title":"JAMA"},{"issue":"10","key":"2174_CR45","doi-asserted-by":"publisher","first-page":"e2019429","DOI":"10.1001\/jamanetworkopen.2020.19429","volume":"3","author":"I Barankay","year":"2020","unstructured":"Barankay I, Reese PP, Putt ME, et al. Effect of patient financial incentives on statin adherence and lipid control: a randomized clinical trial. JAMA Netw Open. 2020;3(10):e2019429.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2174_CR46","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jacl.2022.07.009","volume":"16","author":"RV Garc\u00eda","year":"2022","unstructured":"Garc\u00eda RV, Garc\u00eda JEP, Navas WD, Salmer\u00f3n DM, Mateos DB. Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome. J Clin Lipidol. 2022;16(5):635\u201342.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2174_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/jamacardio.2022.4018","volume":"8","author":"AJ Blood","year":"2023","unstructured":"Blood AJ, Cannon CP, Gordon WJ, et al. Results of a remotely delivered hypertension and lipid program in more than 10 000 patients across a diverse health care network. JAMA Cardiol. 2023;8(1):12\u201321.","journal-title":"JAMA Cardiol"},{"issue":"21","key":"2174_CR48","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1016\/j.jacc.2024.03.388","volume":"83","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Hutchinson HG, Wolski K, et al. A technology-assisted web application for consumer access to a nonprescription statin medication. J Am Coll Cardiol. 2024;83(21):2080\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2174_CR49","doi-asserted-by":"publisher","first-page":"916031","DOI":"10.3389\/fcvm.2022.916031","volume":"9","author":"S Ruiz-Bustillo","year":"2022","unstructured":"Ruiz-Bustillo S, Badosa N, Cabrera-Aguilera I, et al. An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome. Front Cardiovasc Med. 2022;9:916031.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"2174_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/CIRCRESAHA.117.311532","volume":"121","author":"TM Kaufman","year":"2017","unstructured":"Kaufman TM, Duell PB, Purnell JQ, W\u00f3jcik C, Fazio S, Shapiro MD. Application of PCSK9 inhibitors in practice: challenges and opportunities. Circ Res. 2017;121(5):499\u2013501.","journal-title":"Circ Res"},{"issue":"2","key":"2174_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/jep.13451","volume":"27","author":"A O\u00f1atibia-Astibia","year":"2021","unstructured":"O\u00f1atibia-Astibia A, Malet-Larrea A, Gastelurrutia M, Calvo B, Goyenechea E. Community pharmacist interventions to improve adherence to lipid lowering medication and their influence on clinical outcomes: a systematic review and meta-analysis. J Eval Clin Pract. 2021;27(2):451\u201363.","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"2174_CR52","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jacl.2020.04.004","volume":"14","author":"DL Dixon","year":"2020","unstructured":"Dixon DL, Khaddage S, Bhagat S, Koenig RA, Salgado TM, Baker WL. Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: a systematic review and meta-analysis. J Clin Lipidol. 2020;14(3):282-292.e284.","journal-title":"J Clin Lipidol"},{"key":"2174_CR53","doi-asserted-by":"crossref","unstructured":"Elkomos M, Jahromi R, Kelly MS. Pharmacist-led programs to increase statin prescribing: a narrative review of the literature. Pharmacy (Basel). 2022;10(1).","DOI":"10.3390\/pharmacy10010013"},{"issue":"1","key":"2174_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12912-023-01422-6","volume":"23","author":"X Qiu","year":"2024","unstructured":"Qiu X. Nurse-led intervention in the management of patients with cardiovascular diseases: a brief literature review. BMC Nurs. 2024;23(1):6.","journal-title":"BMC Nurs"},{"key":"2174_CR55","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.atherosclerosissup.2021.01.010","volume":"42","author":"M Alings","year":"2020","unstructured":"Alings M, Descamps O, Guillon B, et al. Implementation of clinical practices and pathways optimizing ACS patients lipid management: focus on eight European initiatives. Atheroscler Suppl. 2020;42:e59\u201364.","journal-title":"Atheroscler Suppl"},{"issue":"12","key":"2174_CR56","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1111\/dme.14095","volume":"36","author":"NSR Lan","year":"2019","unstructured":"Lan NSR, Fegan PG, Rankin JM, Bell DA, Watts GF, Yeap BB. Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. Diabet Med. 2019;36(12):1643\u201351.","journal-title":"Diabet Med"},{"issue":"8","key":"2174_CR57","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/imj.15393","volume":"52","author":"SA Hitchen","year":"2022","unstructured":"Hitchen SA, Lan NSR, Ali US, et al. Investigating the effect of an education programme on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery. Intern Med J. 2022;52(8):1354\u201365.","journal-title":"Intern Med J"},{"issue":"3","key":"2174_CR58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imj.15245","volume":"51","author":"SA Hitchen","year":"2021","unstructured":"Hitchen SA, Lan NSR, Hort AL, Rankin JM, Fegan PG, Yeap BB. Managing inpatient hyperglycaemia and initiating sodium-glucose cotransporter 2 inhibitor therapy in the setting of diabetes and acute coronary syndrome. Intern Med J. 2021;51(3):428\u201332.","journal-title":"Intern Med J"},{"issue":"8","key":"2174_CR59","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752\u201362.","journal-title":"Postgrad Med"},{"issue":"5","key":"2174_CR60","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cjco.2023.02.002","volume":"5","author":"Z Taboun","year":"2023","unstructured":"Taboun Z, Naik N, Brown V, et al. Awareness among primary care physicians in canada of guideline recommendations for lowering LDL-cholesterol in high-risk patients. CJC Open. 2023;5(5):357\u201363.","journal-title":"CJC Open"},{"issue":"2","key":"2174_CR61","doi-asserted-by":"publisher","first-page":"020702","DOI":"10.7189\/jogh.07.020702","volume":"7","author":"R Ding","year":"2017","unstructured":"Ding R, Ye P, Zhao S, et al. Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: subgroup analysis of the Dyslipidemia International Study. J Glob Health. 2017;7(2):020702.","journal-title":"J Glob Health"},{"issue":"13","key":"2174_CR62","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","volume":"74","author":"DL Dixon","year":"2019","unstructured":"Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol. 2019;74(13):1728\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2174_CR63","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.amjcard.2018.12.031","volume":"123","author":"A Lowenstern","year":"2019","unstructured":"Lowenstern A, Navar AM, Li S, et al. Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels (A Survey of US Practice in the PALM Registry). Am J Cardiol. 2019;123(7):1011\u20138.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2174_CR64","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12325-023-02716-6","volume":"41","author":"JN McKoy","year":"2024","unstructured":"McKoy JN, Kalich BA, Greene L, et al. LOGAN-CV: a prospective study of a multifaceted intervention targeting United States clinicians to improve guideline-based management of lipid-lowering therapy. Adv Ther. 2024;41(1):451\u201363.","journal-title":"Adv Ther"},{"issue":"5","key":"2174_CR65","doi-asserted-by":"publisher","first-page":"e219211","DOI":"10.1001\/jamanetworkopen.2021.9211","volume":"4","author":"I Barankay","year":"2021","unstructured":"Barankay I, Reese PP, Putt ME, et al. Qualitative exploration of barriers to statin adherence and lipid control: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021;4(5):e219211.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2174_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/clc.23935","volume":"46","author":"NR Desai","year":"2023","unstructured":"Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13\u201321.","journal-title":"Clin Cardiol"},{"issue":"1","key":"2174_CR67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MED.0000000000000842","volume":"31","author":"J Pang","year":"2024","unstructured":"Pang J, Sanfilippo FM, Chan DC, Watts GF. Adherence to pharmacotherapy: sine qua non for reducing cumulative risk of premature coronary disease in familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2024;31(1):22\u201330.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"7","key":"2174_CR68","doi-asserted-by":"publisher","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","volume":"8","author":"CK Bradley","year":"2019","unstructured":"Bradley CK, Wang TY, Li S, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry. J Am Heart Assoc. 2019;8(7):e011765.","journal-title":"J Am Heart Assoc"},{"key":"2174_CR69","doi-asserted-by":"publisher","first-page":"i3283","DOI":"10.1136\/bmj.i3283","volume":"353","author":"A Matthews","year":"2016","unstructured":"Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.","journal-title":"BMJ"},{"issue":"8","key":"2174_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11883-020-00853-9","volume":"22","author":"AJ Nelson","year":"2020","unstructured":"Nelson AJ, Puri R, Nissen SE. Statins in a distorted mirror of media. Curr Atheroscler Rep. 2020;22(8):37.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"2174_CR71","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2174_CR72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","volume":"17","author":"BA Warden","year":"2023","unstructured":"Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of Statin-associated Muscle Symptoms (SAMS): Aa clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19\u201339.","journal-title":"J Clin Lipidol"},{"issue":"22","key":"2174_CR73","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMc2031173","volume":"383","author":"FA Wood","year":"2020","unstructured":"Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182\u20134.","journal-title":"N Engl J Med"},{"issue":"15","key":"2174_CR74","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"11","key":"2174_CR75","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/jan.14025","volume":"75","author":"JP Tan","year":"2019","unstructured":"Tan JP, Cheng KKF, Siah RC. A systematic review and meta-analysis on the effectiveness of education on medication adherence for patients with hypertension, hyperlipidaemia and diabetes. J Adv Nurs. 2019;75(11):2478\u201394.","journal-title":"J Adv Nurs"},{"issue":"5","key":"2174_CR76","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2478\/abm-2022-0026","volume":"16","author":"FF Ismail","year":"2022","unstructured":"Ismail FF, Md Redzuan A, Wen CW. Patient-centered education in dyslipidemia management: a systematic review. Asian Biomed (Res Rev News). 2022;16(5):214\u201336.","journal-title":"Asian Biomed (Res Rev News)"},{"issue":"11","key":"2174_CR77","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1016\/j.pec.2022.06.013","volume":"105","author":"M Papus","year":"2022","unstructured":"Papus M, Dima AL, Viprey M, Schott AM, Schneider MP, Novais T. Motivational interviewing to support medication adherence in adults with chronic conditions: systematic review of randomized controlled trials. Patient Educ Couns. 2022;105(11):3186\u2013203.","journal-title":"Patient Educ Couns"},{"issue":"9","key":"2174_CR78","first-page":"814","volume":"171","author":"NK Choudhry","year":"2011","unstructured":"Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814\u201322.","journal-title":"Arch Intern Med"},{"issue":"11","key":"2174_CR79","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","volume":"387","author":"JM Castellano","year":"2022","unstructured":"Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387(11):967\u201377.","journal-title":"N Engl J Med"},{"key":"2174_CR80","doi-asserted-by":"crossref","unstructured":"Schiele F, P\u00e9rez de Isla L, Arca M, Vlachopoulos C. Is it time for single-pill combinations in dyslipidemia? Am J Cardiovasc Drugs. 2022;22(3):239-249.","DOI":"10.1007\/s40256-021-00498-2"},{"issue":"9","key":"2174_CR81","first-page":"e280","volume":"23","author":"HB Bosworth","year":"2017","unstructured":"Bosworth HB, Brown JN, Danus S, et al. Evaluation of a packaging approach to improve cholesterol medication adherence. Am J Manag Care. 2017;23(9):e280\u20136.","journal-title":"Am J Manag Care"},{"issue":"1","key":"2174_CR82","doi-asserted-by":"publisher","first-page":"e016215","DOI":"10.1161\/JAHA.119.016215","volume":"10","author":"JA Rymer","year":"2021","unstructured":"Rymer JA, Fonseca E, Bhandary DD, Kumar D, Khan ND, Wang TY. Difference in medication adherence between patients prescribed a 30-day versus 90-day supply after acute myocardial infarction. J Am Heart Assoc. 2021;10(1):e016215.","journal-title":"J Am Heart Assoc"},{"key":"2174_CR83","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.2147\/PPA.S149423","volume":"12","author":"CE Kosmas","year":"2018","unstructured":"Kosmas CE, Silverio D, Ovalle J, Montan PD, Guzman E. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Prefer Adherence. 2018;12:2263\u20136.","journal-title":"Patient Prefer Adherence"},{"issue":"16","key":"2174_CR84","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"key":"2174_CR85","doi-asserted-by":"crossref","unstructured":"Bond Z, Scanlon T, Judah G. Systematic review of RCTs assessing the effectiveness of mhealth interventions to improve statin medication adherence: using the behaviour-change technique taxonomy to identify the techniques that improve adherence. Healthcare (Basel). 2021;9(10).","DOI":"10.3390\/healthcare9101282"},{"issue":"2","key":"2174_CR86","doi-asserted-by":"publisher","first-page":"e001017","DOI":"10.1136\/openhrt-2019-001017","volume":"6","author":"SM Shariful Islam","year":"2019","unstructured":"Shariful Islam SM, Farmer AJ, Bobrow K, et al. Mobile phone text-messaging interventions aimed to prevent cardiovascular diseases (Text2PreventCVD): systematic review and individual patient data meta-analysis. Open Heart. 2019;6(2):e001017.","journal-title":"Open Heart"},{"issue":"1","key":"2174_CR87","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11886-017-0811-8","volume":"19","author":"H Klimis","year":"2017","unstructured":"Klimis H, Khan ME, Kok C, Chow CK. The role of text messaging in cardiovascular risk factor optimization. Curr Cardiol Rep. 2017;19(1):4.","journal-title":"Curr Cardiol Rep"},{"issue":"13","key":"2174_CR88","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurheartj\/ehac030","volume":"43","author":"Y Chen","year":"2022","unstructured":"Chen Y, Harris S, Rogers Y, Ahmad T, Asselbergs FW. Nudging within learning health systems: next generation decision support to improve cardiovascular care. Eur Heart J. 2022;43(13):1296\u2013306.","journal-title":"Eur Heart J"},{"issue":"8","key":"2174_CR89","first-page":"1010","volume":"26","author":"K Chen","year":"2020","unstructured":"Chen K, Canfield S, Blackwell J, Houmes S, Jones S, Lindsley J. Optimization of lipid-lowering therapy for high cardiovascular risk patients through electronic medical record reporting and pharmacist evaluation. J Manag Care Spec Pharm. 2020;26(8):1010\u20136.","journal-title":"J Manag Care Spec Pharm"},{"key":"2174_CR90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ahj.2021.08.017","volume":"243","author":"J Plutzky","year":"2022","unstructured":"Plutzky J, Benson MD, Chaney K, et al. Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. Am Heart J. 2022;243:15\u201327.","journal-title":"Am Heart J"},{"key":"2174_CR91","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijmedinf.2019.06.024","volume":"129","author":"BA Van Dort","year":"2019","unstructured":"Van Dort BA, Zheng WY, Baysari MT. Prescriber perceptions of medication-related computerized decision support systems in hospitals: a synthesis of qualitative research. Int J Med Inform. 2019;129:285\u201395.","journal-title":"Int J Med Inform"},{"issue":"5","key":"2174_CR92","doi-asserted-by":"publisher","first-page":"e2110255","DOI":"10.1001\/jamanetworkopen.2021.10255","volume":"4","author":"MS Patel","year":"2021","unstructured":"Patel MS, Small DS, Harrison JD, et al. Effect of behaviorally designed gamification with social incentives on lifestyle modification among adults with uncontrolled diabetes: a randomized clinical trial. JAMA Netw Open. 2021;4(5):e2110255.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2174_CR93","doi-asserted-by":"publisher","first-page":"e2116256","DOI":"10.1001\/jamanetworkopen.2021.16256","volume":"4","author":"AK Agarwal","year":"2021","unstructured":"Agarwal AK, Waddell KJ, Small DS, et al. Effect of gamification with and without financial incentives to increase physical activity among veterans classified as having obesity or overweight: a randomized clinical trial. JAMA Netw Open. 2021;4(7):e2116256.","journal-title":"JAMA Netw Open"},{"issue":"21","key":"2174_CR94","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.124.069531","volume":"149","author":"AC Fanaroff","year":"2024","unstructured":"Fanaroff AC, Patel MS, Chokshi N, et al. Effect of gamification, financial incentives, or both to increase physical activity among patients at high risk of cardiovascular events: the BE ACTIVE randomized controlled trial. Circulation. 2024;149(21):1639\u201349.","journal-title":"Circulation"},{"issue":"11","key":"2174_CR95","doi-asserted-by":"publisher","first-page":"e20839","DOI":"10.2196\/20839","volume":"22","author":"MA Hyder","year":"2020","unstructured":"Hyder MA, Razzak J. Telemedicine in the United States: an introduction for students and residents. J Med Internet Res. 2020;22(11):e20839.","journal-title":"J Med Internet Res"},{"issue":"1","key":"2174_CR96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jacl.2022.12.003","volume":"17","author":"TJ Schubert","year":"2023","unstructured":"Schubert TJ, Clegg K, Karalis D, et al. Impact of telehealth on the current and future practice of lipidology: a scoping review. J Clin Lipidol. 2023;17(1):40\u201354.","journal-title":"J Clin Lipidol"},{"issue":"25","key":"2174_CR97","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.041974","volume":"140","author":"R Khera","year":"2019","unstructured":"Khera R, Valero-Elizondo J, Das SR, et al. Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017. Circulation. 2019;140(25):2067\u201375.","journal-title":"Circulation"},{"key":"2174_CR98","doi-asserted-by":"crossref","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939\u2013949.","DOI":"10.1093\/ehjacc\/zuac123"},{"key":"2174_CR99","doi-asserted-by":"crossref","unstructured":"Mansfield BS, Mohamed F, Larouche M, Raal FJ. The hurdle of access to emerging therapies and potential solutions in the management of dyslipidemias. J Clin Med. 2024;13(14).","DOI":"10.3390\/jcm13144160"},{"issue":"11","key":"2174_CR100","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","volume":"2","author":"AM Navar","year":"2017","unstructured":"Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2(11):1217\u201325.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2174_CR101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","volume":"17","author":"TT Chiou","year":"2023","unstructured":"Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic. J Clin Lipidol. 2023;17(1):73\u20137.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2174_CR102","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/03007995.2017.1391082","volume":"34","author":"F Barkas","year":"2018","unstructured":"Barkas F, Elisaf M. National hyperlipidemia management policies improve lipid target attainment in clinical practice. Curr Med Res Opin. 2018;34(2):301\u20133.","journal-title":"Curr Med Res Opin"},{"key":"2174_CR103","doi-asserted-by":"crossref","unstructured":"Dixon DL, Saseen JJ. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence. J Am Pharm Assoc (2003). 2021;61(3):e83-e85.","DOI":"10.1016\/j.japh.2020.12.009"},{"issue":"7","key":"2174_CR104","first-page":"924","volume":"27","author":"A Hung","year":"2021","unstructured":"Hung A, Blalock DV, Miller J, et al. Impact of financial medication assistance on medication adherence: a systematic review. J Manag Care Spec Pharm. 2021;27(7):924\u201335.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"2174_CR105","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/1559827617729634","volume":"13","author":"RR Bailey","year":"2019","unstructured":"Bailey RR. Goal setting and action planning for health behavior change. Am J Lifestyle Med. 2019;13(6):615\u20138.","journal-title":"Am J Lifestyle Med"},{"issue":"9","key":"2174_CR106","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/j.amjmed.2019.04.002","volume":"132","author":"X Jia","year":"2019","unstructured":"Jia X, Al Rifai M, Ramsey DJ, et al. Association between lipid testing and statin adherence in the veterans affairs health system. Am J Med. 2019;132(9):e693\u2013700.","journal-title":"Am J Med"},{"issue":"5","key":"2174_CR107","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.amjmed.2021.11.011","volume":"135","author":"JS Rana","year":"2022","unstructured":"Rana JS, Virani SS, Moffet HH, et al. Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification. Am J Med. 2022;135(5):603\u20136.","journal-title":"Am J Med"},{"issue":"4","key":"2174_CR108","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2022.05.003","volume":"16","author":"C Tran","year":"2022","unstructured":"Tran C, Vo V, Taylor P, Koehn DA, Virani SS, Dixon DL. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022;16(4):491\u20137.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2174_CR109","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2023.02.003","volume":"17","author":"SS Virani","year":"2023","unstructured":"Virani SS, Aspry K, Dixon DL, et al. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023;17(2):208\u201318.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"2174_CR110","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/MOL.0000000000000835","volume":"33","author":"LK Jones","year":"2022","unstructured":"Jones LK, Sturm AC, Gionfriddo MR. Translating guidelines into practice via implementation science: an update in lipidology. Curr Opin Lipidol. 2022;33(6):336\u201341.","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"2174_CR111","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11883-023-01090-6","volume":"25","author":"M Sarkies","year":"2023","unstructured":"Sarkies M, Jones LK, Pang J, Sullivan D, Watts GF. How can implementation science improve the care of familial hypercholesterolaemia? Curr Atheroscler Rep. 2023;25(4):133\u201343.","journal-title":"Curr Atheroscler Rep"},{"issue":"20","key":"2174_CR112","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2021.04.001","volume":"77","author":"CL Miller","year":"2021","unstructured":"Miller CL, Kontorovich AR, Hao K, et al. Precision medicine approaches to vascular disease: JACC Focus Seminar 2\/5. J Am Coll Cardiol. 2021;77(20):2531\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2174_CR113","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12997\/jla.2024.13.2.111","volume":"13","author":"W Masson","year":"2024","unstructured":"Masson W, Corral P, Nogueira JP, Lavalle-Cobo A. Applicability of artificial intelligence in the field of clinical lipidology: a narrative review. J Lipid Atheroscler. 2024;13(2):111\u201321.","journal-title":"J Lipid Atheroscler"},{"key":"2174_CR114","doi-asserted-by":"publisher","first-page":"132315","DOI":"10.1016\/j.ijcard.2024.132315","volume":"412","author":"M Athar","year":"2024","unstructured":"Athar M. Potentials of artificial intelligence in familial hypercholesterolemia: advances in screening, diagnosis, and risk stratification for early intervention and treatment. Int J Cardiol. 2024;412:132315.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2174_CR115","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13012-021-01108-0","volume":"16","author":"LK Jones","year":"2021","unstructured":"Jones LK, Tilberry S, Gregor C, et al. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis. Implement Sci. 2021;16(1):40.","journal-title":"Implement Sci"},{"issue":"1","key":"2174_CR116","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12874-022-01661-2","volume":"22","author":"MN Sarkies","year":"2022","unstructured":"Sarkies MN, Francis-Auton E, Long JC, Pomare C, Hardwick R, Braithwaite J. Making implementation science more real. BMC Med Res Methodol. 2022;22(1):178.","journal-title":"BMC Med Res Methodol"},{"key":"2174_CR117","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13012-015-0209-1","volume":"10","author":"BJ Powell","year":"2015","unstructured":"Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10:21.","journal-title":"Implement Sci"},{"issue":"1","key":"2174_CR118","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/chp.1340210109","volume":"21","author":"G Mowatt","year":"2001","unstructured":"Mowatt G, Grimshaw JM, Davis DA, Mazmanian PE. Getting evidence into practice: the work of the Cochrane Effective Practice and Organization of care Group (EPOC). J Contin Educ Health Prof. 2001;21(1):55\u201360.","journal-title":"J Contin Educ Health Prof"},{"issue":"1","key":"2174_CR119","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50.","journal-title":"Implement Sci"},{"key":"2174_CR120","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, Harden SM, Gaglio B, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.","journal-title":"Front Public Health"},{"key":"2174_CR121","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ahj.2018.09.003","volume":"206","author":"LL Zullig","year":"2018","unstructured":"Zullig LL, Egbuonu-Davis L, Trasy A, Oshotse C, Goldstein KM, Bosworth HB. Countering clinical inertia in lipid management: Expert workshop summary. Am Heart J. 2018;206:24\u20139.","journal-title":"Am Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02174-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:05:54Z","timestamp":1772096754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02174-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2174"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02174-8","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"28 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NSRL has received research funding from Sanofi as part of a Clinical Fellowship in Endocrinology and Diabetes, education support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Novartis and Pfizer, speaker honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Novartis and Sanofi, and has participated in advisory boards for Eli Lilly. RTC has nothing to declare. SJN has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Cyclarity, Eli Lilly, Esperion, Resverlogix, New Amsterdam Pharma, Novartis, InfraReDx and Sanofi-Regeneron and is also a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Cyclarity, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi- Regeneron, Vaxxinity, CSL Seqirus, and Novo Nordisk. GD reports paid lectures from AstraZeneca, Pfizer and Amgen and provides consultancy services and has equity interest in Artrya Ltd. GFW has received honoraria for advisory boards and research grants from Amgen, Arrowhead, Esperion, Gemphire, Kowa, Novartis, Pfizer, Sanofi, Novo Nordisk and Regeneron. AJN has received research support from AstraZeneca, Amgen, Eli Lilly, Novartis and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Sequiris, Eli Lilly, GSK, Sanofi Pasteur and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"9"}}